Jacobson Mark L. 4
4 · Axsome Therapeutics, Inc. · Filed Sep 17, 2025
Insider Transaction Report
Form 4
Jacobson Mark L.
Chief Operating Officer
Transactions
- Sale
Common Stock
2025-09-16$114.23/sh−40,000$4,569,200→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-16−15,000→ 0 totalExercise: $4.85From: 2018-09-13Exp: 2027-09-13→ Common Stock (15,000 underlying) - Sale
Common Stock
2025-09-16$116.19/sh−5,783$671,927→ 0 total - Exercise/Conversion
Common Stock
2025-09-16$4.85/sh+15,000$72,750→ 40,000 total - Exercise/Conversion
Common Stock
2025-09-16$4.95/sh+25,000$123,750→ 25,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-16−25,000→ 0 totalExercise: $4.95From: 2018-03-15Exp: 2027-03-15→ Common Stock (25,000 underlying)
Footnotes (6)
- [F1]Represents the sale of underlying shares of previously exercised stock options.
- [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan.
- [F3]Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.
- [F4]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- [F5]Represents the sale price of all shares in an open market transaction.
- [F6]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $112.93 and $116.87.